U.S. Investors Seek China Medicines
This is a China news story, published by CNBC, that relates primarily to Trump news.
China news
For more China news, you can click here:
more China newsTrump news
For more Trump news, you can click here:
more Trump newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsCNBC news
For more news from CNBC, you can click here:
more news from CNBCAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Chinese biotech companies. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest large pharmaceutical companies news, more large pharmaceutical companies news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
other large pharmaceutical companiesCNBC
•Health
Health
U.S. investors, Big Pharma race to find new medicines in China
84% Informative
Almost 30% of Big Pharma deals with at least $50 million up front came from China last year .
Increase in China deals comes as President Trump and U.S. policymakers pursue protectionist policies in technology.
Chinese companies are creating better molecules than ever before and more of them.
Buyers have figured out a business model to essentially import the drugs through licensing deals.
U.S. biopharma deals with Chinese biotech companies could become more common.
Gilead has seen a "substantial shift" in the quality and quantity of assets being developed in China .
Some see it as a way to bring down the price of prescription drugs.
Others worry it could hobble U.K. companies if Merck and other large pharmaceutical companies pass on acquiring American startups.
VR Score
89
Informative language
91
Neutral language
43
Article tone
semi-formal
Language
English
Language complexity
52
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links